WVXU: COVID-19, lung and brain images and stroke risk

UC researchers find lung, brain scans of COVID patients may detect looming stroke

University of Cincinnati researchers say for the first time they have a visual correlation between the severity of COVID-19 in the lungs and the effect on patients' brains. This early indicator could be key in preventing such neurological problems, like stroke.

Lead author of the recent study Abdelkader Mahammedi, MD, assistant professor of radiology at the University of Cincinnati and a UC Health neuroradiologist says, "We came out with a scoring system in the lungs where the idea is to score the severity of the lung disease. And based on the severity of the CT scan, we can help physicians predict the prevalence of the abnormality in the brain."

How much time is there before patients possibly suffer a stroke or some other neurological problem?

Mahammedi says there is some variation. "Typically six to eleven days when you have the likelihood of having some complication in the brain," he says.

He led the trial with Achala Vagal, MD, professor and vice chair of research in the department of radiology.

Listen to the full WVXU, 91.7 FM story.

Read more about the study.

The study was also featured in a Local 12 news story. Trade publications Radiology Business and Diagnostic Imaging also reported on this study.

Featured photo of CT machine by Colleen Kelley. 

Impact Lives Here

The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.

Stay up on all UC's COVID-19 stories, or take a UC virtual visit and begin picturing yourself at an institution that inspires incredible stories.

Related Stories

3

Lettuce grow up with seeds of innovation like UC alumna

February 13, 2025

80 Acres Farms, a Cincinnati-based vertical farming leader, continues its rapid expansion with $115 million in new capital and the acquisition of Israeli biotech firm Plantae Bioscience. Co-founded in 2015, the company has now raised over $400 million, solidifying its position as a major player in controlled-environment agriculture.

Debug Query for this